September 15, 2025 4:41pm

As I have written, cell and gene therapy sector investors are existing in a “catalyst vacuum”

Subject to “riding the skids of uncle algo and his electronic trading dwarfs”

Never leave an investor uninformed!  

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in your portfolio for the short-term

 

Monday’s RegMed Investors’ (RMi) pre-open: Support is TBD … https://www.regmedinvestors.com/articles/14105

RMi Research note: Sanofi (SAN-PA) has frozen R&D investment decisions in the U.K. … https://www.regmedinvestors.com/articles/14106

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed UP +49.23 points or +0.11%, the S&P closed UP +30.99 points or +0.47% while the Nasdaq closed UP +207.647 points or +0.94%

  • Theme of the session, U.S.-China trade negotiations going well while trading positions for the Fed rate event this week

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy

  • The New York Fed’s Empire State Manufacturing Index slid 21 points to a -8.7 reading, the 1st negative print since June and well below the estimate for 4.5. Readings below zero represent contraction. Internally, the new orders index collapsed, falling 35 points, while shipments were down 30 points. Both the prices paid and prices received measures showed small declines, while employment was little changed.

Monday’s my 40-company covered sector’s advance/decline line opened positive with 22 incliners, 14 decliners and 1 flat ending with a negative close of 17 incliners, 22 decliners and 1 flat

Metrics:  Friday, the IBB was down -0.26%, the XBI was down -0.69% while the VIX was up +0.88 points or +5.97% at 15.64

 

Q3, September – 1 holiday, 5 negative and 5 positive closes

  • August – 12 negative and 9 positive closes
  • July – 1 market holiday, 13 positive and 9 negative closes

 

Monday Closing UP (10 of 17) 

  • CRISPR Therapeutics (CRSP +$1.58 after Friday’s +$0.37),
  • BioNTech SE (BNTX +$1.14 after Friday’s -$7.57),
  • Beam Therapeutics (BEAM +$0.68 after Friday’s -$0.95),
  • Mesoblast (MESO +$0.64),
  • Moderna (MRNA +$0.37 after Friday’s -$1.88),
  • BioLife Solutions (BLFS +$0.29 after Friday’s -$1.23),
  • Intellia Therapeutics NTLA +$0.15 after Friday’s $0.00),
  • Compass Therapeutics (CMPX +$0.12 after Friday’s +$0.04),
  • Cellectis SA (CLLS +$0.10),
  • Solid Biosciences (SLDB +$0.10 after Friday’s +$0.08),

Flat (0)

Monday’s Closing DOWN (10 of 22): 

  • Alnylam Pharmaceuticals (ALNY -$4.62 after Friday’s -$2.69),
  • Ionis Pharmaceuticals (IONS -$2.06 after Friday’s -$0.88),
  • uniQure NV (QURE -$1.65),
  • Supernus Therapeutics (SUPR -$1,47 after Friday’s -$1.20),
  • Lenz Therapeutics (LENZ -$1.33 after Friday’s +$0.52),
  • Ultragenyx Pharmaceuticals (RARE -$1.31 after Friday’s -$0.92)
  • IQV Holdings (IQV -$1.25 after Friday’s -$3.47),
  • Vertex Pharmaceuticals (VRTX -$1.12 after Friday’s -$2.84),
  • Arrowhead Pharmaceuticals (ARWR -$1.05 after Friday’s $0.00),
  • Vericel (VCEL -$0.76 after Friday’s -$1.35),

 

The BOTTOM LINE:  More of the … WHYs …

We seem to be always waiting for … something i.ie., anything

  • Econs are poison to “our” universe …
  • Indexes moved higher yet cell and gene therapy sector equities dived on Monday as US-China trade talks unfolded in Madrid and investors awaited a pivotal Fed meeting – Wednesday.
  • After coming off a strong week in which the Nasdaq and the S&P 500 saw their best weekly showings since early August, while the Dow snapped a 2-week losing streak.
  • And, as treasury yields fell slightly; the 30-year Treasury yield (^TYX) fell about 3 basis points to 4.65% after rising to nearly touch 5% earlier this month. The 10-year Treasury yield (^TNX) fell over 2 basis points to roughly 4.04%.

Bottom Line … a flight to some-sort-of-safety!

 

September: understand the “flow” …

  • 9/15 - Monday closed negative with 17 positive, 22 negative and 1 flat
  • 9/12 – Friday closed negative with 4 positive, 34 negative and 2 flats
  • 9/11 - Thursday closed positive with 27 positive, 11 negative and 2 flats
  • 9/10 – Wednesday closed negative with 13 positive, 26 negative and 1 flat
  • 9/9 - Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 9/8 – Monday closed negative with 10 positive, 28 negative and 2 flats
  • 9/5 - Friday closed positive with 35 positive, 5 negative and 0 flat
  • 9/4 – Thursday closed negative with 17 positive, 21 negative and 2 flats
  • 9/3 - Wednesday closed positive with 22 positive, 16 negative and 2 flats
  • 9/2 -Tuesday closed positive with 22 positive, 18 negative and 0 flat
  • 9/1 - Monday was a holiday

 

Interesting: President Trump suggested that companies should report earnings results on a semi-annual basis — or every 6 months — rather than every Q.

 

Also, the market has priced in a 25-basis point cut to interest rates, the 1st of this year. The biggest question now is what the US central bank's rate path will be for the remainder of 2025.

 

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Beam Therapeutics (BEAM)
  • Friday: Solid Biosciences (SLDB), Lenz Therapeutics (LENZ) and CRISPR Therapeutics (CRSP)

The worst three (3) in the session: 

  • Monday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and uniQure NV (QURE)
  • Friday: BioNTech (BNTX), Vertex (VRTX) and IQV Holdings (IQV)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.